This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nikitakis, N. G. Articles by Sauk, J. J. Search for Related Content PubMed PubMed Citation Articles by Nikitakis, N. G. Articles by Sauk, J. J.

The Nonsteroidal Anti-inflammatory Drug Sulindac Causes Down-Regulation of Signal Transducer and Activator of Transcription 3 in Human Oral Squamous Cell Carcinoma Cells

Departments of Diagnostic Sciences and Pathology [N. G. N., J. J. S.] and of Pathology [A. W. H.], and Greenebaum Cancer Center [A. W. H., J. J. S.], University of Maryland, Baltimore, Maryland 21201-1586

The nonsteroidal anti-inflammatory drug sulindac exerts a significant antineoplastic effect on several types of human cancers including oral squamous cell carcinoma (SCCa). Because constitutive activation of signal transducer and activator of transcription 3 (Stat3) has been linked to carcinogenesis of various tumors including head and neck SCCa, we studied whether sulindac treatment affects the Stat3 signaling pathway in oral SCCa cells. Western blot experiments showed that short-term treatment of cells with sulindac resulted in a large reduction of phosphorylated Stat3, without significantly affecting Stat3 protein levels. In contrast, 3 days of sulindac treatment eliminated both phosphorylated and unphosphorylated Stat3 protein levels. Also, sulindac treatment exerted a significant time-dependent cell growth-inhibitory effect on oral SCCa cells under the same conditions shown to induce Stat3 down-modulation. The sulfone metabolite of sulindac, which lacks cyclooxygenase-inhibitory activity, did not affect either Stat3 expression or Stat3 phosphorylation. Antisense oligonucleotide treatment against peroxisome proliferator-activated receptor did not attenuate the ability of sulindac to down-regulate Stat3. Our results suggest that down-modulation of Stat3 can be induced by sulindac treatment, thus possibly contributing to the antineoplastic effect of this drug.

This article has been cited by other articles:

				Y. Zhang, X.-W. Wang, D. Jelovac, T. Nakanishi, M.-h. Yu, D. Akinmade, O. Goloubeva, D. D. Ross, A. Brodie, and A. W. Hamburger The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells PNAS, July 12, 2005; 102(28): 9890 - 9895. [Abstract] [Full Text] [PDF]

				H. Siavash, N.G. Nikitakis, and J.J. Sauk SIGNAL TRANSDUCERS AND ACTIVATORS OF TRANSCRIPTION: INSIGHTS INTO THE MOLECULAR BASIS OF ORAL CANCER Crit. Rev. Oral. Biol. Med., September 1, 2004; 15(5): 298 - 307. [Abstract] [Full Text] [PDF]

				L. Klampfer, J. Huang, L.-A. Swaby, and L. Augenlicht Requirement of Histone Deacetylase Activity for Signaling by STAT1 J. Biol. Chem., July 16, 2004; 279(29): 30358 - 30368. [Abstract] [Full Text] [PDF]

				L. Klampfer, J. Huang, T. Sasazuki, S. Shirasawa, and L. Augenlicht Inhibition of Interferon {gamma} Signaling by the Short Chain Fatty Acid Butyrate Mol. Cancer Res., September 1, 2003; 1(11): 855 - 862. [Abstract] [Full Text] [PDF]

				M. Wick, G. Hurteau, C. Dessev, D. Chan, M. W. Geraci, R. A. Winn, L. E. Heasley, and R. A. Nemenoff Peroxisome Proliferator-Activated Receptor-gamma Is a Target of Nonsteroidal Anti-Inflammatory Drugs Mediating Cyclooxygenase-Independent Inhibition of Lung Cancer Cell Growth Mol. Pharmacol., November 1, 2002; 62(5): 1207 - 1214. [Abstract] [Full Text] [PDF]